CTI Clinical Trial and Consulting Services’ Post

Excited to kickoff one of the top conference for clinical operations. My main goal: Learn, discuss and share ideas on how Data & AI can transform clinical trial execution to improve patient outcome around the world. #SCOPEsummit #perficient #data #ai

Excited to Listen Demet Aybar, CEO of US Lab Partners LLC, engaging presentation on Day 2 of the 7th Alcor Drug Discovery Platform! Demet will share insights on 'Accelerating Drug Platform Development,' offering invaluable strategies to expedite the journey from concept to market. Don't miss this opportunity to learn from a leader in accelerating pharmaceutical innovation! #AlcorDrugDiscovery #DrugPlatformDevelopment #Innovation #DrugDiscovery #Preclinical #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits

[📆 #Event - #DigitalTwins] “Le jumeau numérique en santé” Webinar has just ended. We would like to express our gratitude to POC Media and Florent Detroy for their trust, as well as to the other speakers for participating in this roundtable. For those who were unable to attend, we'll be sure to relay the replay of the show when it becomes available. Stay tuned ! As a reminder, Alexandre Templier (President) spoke about how “pragmatic” digital twins are revolutionizing decision-making in the pharmaceutical industry to drive drug development (from clinical development to market access and portfolio management). #artificialintelligence #DigitalHealth #ClinicalTrials

Timelines for submissions in #UK and #Germany are back to normal! Whatch this video where our experts will provide an update on recent early-phase #regulatory #timelines, resulting in trial efficiencies and accelerated approvals for #biopharmaceutical companies. #MHRA #BfArM #clinicalresearch #clinicaltrials

🚀 💊 Post-pandemic changes and the introduction of EU-CTR 536/2014 are providing a favorable regulatory environment for drug developers in key strategic regions. In this recording from our recent webinar “Accelerating early phase development in the UK and Germany,” hear from Parexel clinical research experts Amanda Knaggs, Peter Dewland, and Thin Thin Mencarini as they provide an update on recent early-phase regulatory timelines, resulting in trial efficiencies and accelerated approvals for biopharmaceutical companies. Watch the full video here: https://lnkd.in/gUBWcd57 #ParexelBiotech #Regulatory #EarlyPhase #Biopharma

How do you ensure your projects align with your organization's strategic vision? 🌐 Learn from Danette Astolfi, Senior Director of Project Management at Elevar Therapeutics, at our Boston conference. She'll discuss aligning projects and programs with business goals, sharing strategies from a leading pharmaceutical company. What challenges are you facing in strategic alignment? Let's find solutions together—reserve your seat today! https://lnkd.in/dmKigmrk #PPM #Boston #PharmaConference #StrategicAlignment

🌐 CellSEP Hosts Global Clinical Trial Liaison from Regeneron 🌐 We at CellSEP had the distinct honor of hosting Novell McGloster, MS.Ed, Global Clinical Trial Liaison from Regeneron.. This meeting marks a significant milestone in our ongoing commitment to fostering collaborative relationships with industry leaders in #biotechnology and #pharmaceuticals. Our discussions centered on groundbreaking advancements in clinical trials and the potential for future collaborative projects that align with our mission of innovation in Cell Isolation and Analytics Laboratories. We are immensely grateful for this opportunity to exchange knowledge and ideas with a global leader in biotech! Potential collaborations like these underscore our dedication to staying at the forefront of advancements in the field, ultimately contributing to the development of life-changing medical therapies. #CellSEP #Regeneron #ClinicalTrials #BiotechCollaboration #researchanddevelopment #innovationinpharma

𝐈𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐞𝐝 𝐢𝐧 𝐃𝐫𝐮𝐠 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧𝐬? 🤑 𝐂𝐚𝐫𝐫𝐲 𝐨𝐧 𝐫𝐞𝐚𝐝𝐢𝐧𝐠... A recent deal between Sanofi and Recordati highlights how pharmaceutical acquisitions can significantly impact patient access, treatment availability, and corporate strategy. Sanofi sold the global rights to Enjaymo, a treatment for cold agglutinin disease (CAD), to Recordati for $825 million upfront, with an additional $250 million contingent on future sales performance—bringing the total deal potential to over $1 billion. We cover this and more in our latest Imagine Biotech newsletter. See comments section for more.

🚀 💊 Post-pandemic changes and the introduction of EU-CTR 536/2014 are providing a favorable regulatory environment for drug developers in key strategic regions. In this recording from our recent webinar “Accelerating early phase development in the UK and Germany,” hear from Parexel clinical research experts Amanda Knaggs, Peter Dewland, and Thin Thin Mencarini as they provide an update on recent early-phase regulatory timelines, resulting in trial efficiencies and accelerated approvals for biopharmaceutical companies. Watch the full video here: https://lnkd.in/gUBWcd57 #ParexelBiotech #Regulatory #EarlyPhase #Biopharma

Tomorrow, we're teaming up with FINGERPOST for a panel discussion on the crucial role of market access in the biotech industry. This event is a must for startup biotechs, industry investors and personnel from large pharmaceutical companies, as it promises to broaden participants’ understanding of market access and its potential to shape drug development’s future. Attendees will learn the importance and timing of integrating market access considerations into their commercial planning. Save your spot: https://bit.ly/3zRUFWb